Betaferon न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

betaferon

bayer new zealand limited - interferon beta-1b 0.25mg (20% excess in quantity filled) - injection with diluent - 8 miu - active: interferon beta-1b 0.25mg (20% excess in quantity filled) excipient: albumin hydrochloric acid mannitol sodium hydroxide hydrochloric acid sodium chloride water for injection - betaferon is indicated for: · the treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent magnetic resonance imaging (mri) lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded, · the treatment of ambulatory patients, with relapsing-remitting multiple sclerosis characterised by at least two attacks of neurological dysfunction over a two year period followed by complete or incomplete recovery. · the reduction of frequency and severity of clinical relapses and for slowing the progression of disease in patients with secondary progressive multiple sclerosis

Fucidin न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

fucidin

leo pharma limited - sodium fusidate 250mg; sodium fusidate 250mg - film coated tablet - 250 mg - active: sodium fusidate 250mg excipient: colloidal silicon dioxide crospovidone gelatin hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide active: sodium fusidate 250mg excipient: colloidal silicon dioxide crospovidone dl-alpha tocopheryl acetate hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified talc titanium dioxide - treatment of localised as well as generalised staphylococcal infections (e.g. abscesses, furunculosis, wound infections, pneumonia, peritonitis, osteomyelitis, septicaemia, enteritis and otorhinolaryngeal infections).